signaling

A unique collection of 2080 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；

A unique collection of 2771 compounds targeting CNS signaling for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 759 cytoskeleton-related compounds, can be used for HTS and HCS；

A unique collection of 729 compounds targeting NF-κB signaling for high throughput screening and high content screening;

A unique collection of 1660 neurotransmitter receptor compounds, can be used for HTS and HCS screening；

A unique collection of 1197 stem cell differentiation signaling targeted compounds for high throughput and high content screening;

A unique collection of 604 compounds targeting cytokine signaling for high throughput screening and high content screening for drug discovery;

A unique collection of 263 kinase inhibitors regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of 540 gut microbial metabolites which can be used for HTS and HCS;

A unique collection of 950 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A unique collection of 237 Wnt Hedgehog Notch signaling targeted compounds for high throughput and high content screening;

A unique collection of 631 nuclear receptor signaling targeted compounds for high throughput and high content screening;

A unique collection of 4940 anti-inflammation compounds effective for high throughput screening and high content screening.

A unique collection of 2840 kinase inhibitors regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;

Well-chosen 1246 compounds with unique structures targeting nervous system;

791 peptides can be used in peptide drug development and signaling transduction and mechanism study;

A unique collection of 3580 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1702 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；

A unique collection of 924 compounds targeting endocrine system for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 8700 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

A unique collection of 1779 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 9730 inhibitors for research in cell signaling, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 415 JAK STAT signaling targeted compounds for high throughput and high content screening;

A unique collection of 779 ferroptosis signaling pathway related compounds, a powerful tool for new target identification, drug discovery, and mechanism study；

A unique collection of 610 compounds targeting PI3K Akt mTOR signaling for research in PI3K Akt mTOR signaling, and drug discovery in diseases involved with PI3K Akt mTOR signaling;

Well-chosen 338 GPCR targeting compounds with unique structures;

A unique collection of 986 compounds with anti-AD activities or acting on main drug targets of AD can be used for HTS and HCS.

A unique collection of 223 endoplasmic reticulum stress (ER stress) related compounds used for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 140 calcium channel blockers and agonists for high throughput and high content screening;

A unique collection of 142 microtubule-targeted compounds can be used in HTS and HCS;

A unique collection of 580 compounds derived from traditional Chinese medicines (TCMs) for promoting blood circulation and removing blood stasis.

A unique collection of 149 neuroregeneration related compounds for high throughput and high content screening;

A unique collection of 2440 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study；

A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related diseases;

A unique collection of 184 TGF-beta Smad signaling targeted compounds for high throughput and high content screening;

A unique collection of 2240 reprogramming signaling pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

A unique collection of 317 osteogenesis related compounds for high throughput and high content screening;

A unique collection of 941 glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer;

A unique collection of 3150 anticancer drugs for high throughput screening (HTS) and high content screening (HCS);

80 well-chosen unique AMPK-targeted small molecules；

A unique collection of 385 bioactive lipids related compounds for high throughput screening (HTS) and high content screening (HCS), including Agonists & Antagonists, Endocannabinoids, Farnesyl geranylgeranyl derivates, HETEs deHETEs, hepoxilins, Polyunsa

A unique collection of 2545 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 188 compounds targeting histaminergic receptor and melatonin receptor for high throughput screening (HTS) and high content screening (HCS) for new drugs;

Well-chosen 1468 anti-tumor compounds with unique structures;